U.S. stocks finished up across the board Tuesday as time runs out for Greece to stay in the Euro. Greek banks are set to run out of cash in a matter of days. Chancellor Angel Merkel is facing renewed pressure in Germany to cut Greece out of the eurozone but has said that the door was still open for a deal proposal. U.S. crude fell for a second day, weighed down by concerns of a Chinese slowdown and the Greek crisis. Iran has also made clear during nuclear deal talks that it will add more supply to the market should sanctions be lifted. Falling oil prices hit energy stocks. Consol Energy (CNX) was one of the worst performers on the S&P 500, the stock is down almost 40 percent since the start of the year. The Commerce Department announced on Tuesday that the U.S. trade gap widened 2.9 percent in May. The strong dollar and European turmoil overseas extended the downward trend in U.S. exports (outside of oil) which are down 4.5 percent from last year's numbers. Overseas, Samsung (SSNLF) has seen its profit slide for the 7th consecutive quarter. The South Korean, electronics company missed earnings estimates following underwhelming sales of its new Galaxy S6 smartphones. The tech giant has struggled with supply shortages and competition from Apple (AAPL). The stock has dropped around 7 percent this year.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.